Literature DB >> 35694088

Effect of the enhanced recovery after surgery protocol on recovery after laparoscopic myomectomy: a systematic review and meta-analysis.

Yulian Chen1, Mingru Fu2, Guifen Huang2, Jiao Chen3.   

Abstract

Background: Surgery is the recommended treatment for uterine leiomyoma but it still has issues like postoperative complications and slow recovery. The enhanced recovery after surgery (ERAS) protocol could probably reduce traumatic stress and promote the rapid postoperative recovery of patients, but there are controversies for the results of different studies. This meta-analysis was performed to resolve the controversies and provide evidence for the application of ERAS in gynecology.
Methods: The PubMed, Embase, Ovid, CNKI (China), Wanfang Data (China), and Google Scholar databases were searched to recruit all studies on the application of ERAS in laparoscopic myomectomy up to November 2021. The inclusion criteria of studies was established according to the PICOS principles. the Cochrane RoB 2.0 and Newcastle-Ottawa Scale (NOS) scale were used to assess the bias of the studies, RevMan 5.3 software was used for meta-analysis.
Results: Ten studies that met the criteria were finally included with 1,441 participants. Eight of them were randomized controlled trials (RCTs) and two were cohort studies, all of them were with low level of bias. Meta-analysis showed that ERAS protocol after laparoscopic myomectomy could significantly shorten the first time getting out of bed after surgery [mean difference (MD) =-4.85; 95% confidence interval (CI): (-7.35, -2.36); P=0.0001], the first defecation time after surgery [MD =-4.69; 95% CI: (-5.68, -3.69); P<0.00001], and the postoperative hospital stay [MD =-1.32, 95% CI: (-2.08, -0.56); P=0.0007]. It could also markedly reduce the patient readmission rate [odds ratio (OR) =0.42; 95% CI: (0.23, 0.76); P=0.004], and notably reduced the incidence of complications [OR =0.37; 95% CI: (0.22, 0.61); Z=3.82; P=0.0001]. Yet, the cost of the ERAS protocol was not significantly different from that of routine care [MD =-127.76, 95% CI: (-997.19, 741.66); P=0.77]. Discussion: The application of ERAS protocol after gynecological laparoscopic myomectomy can shorten the first defecation time, first time out of bed, hospital stay, and reduce the readmission rate as well as the incidence of postoperative complications, without additional costs. But still there was heterogeneity among the studies, the topic still deserved further exploration. 2022 Gland Surgery. All rights reserved.

Entities:  

Keywords:  Enhanced recovery after surgery (ERAS); laparoscopy; myomectomy

Year:  2022        PMID: 35694088      PMCID: PMC9177272          DOI: 10.21037/gs-22-168

Source DB:  PubMed          Journal:  Gland Surg        ISSN: 2227-684X


  22 in total

1.  Enhanced Recovery Pathways for Improving Outcomes After Minimally Invasive Gynecologic Oncology Surgery.

Authors:  Jocelyn S Chapman; Erika Roddy; Stefanie Ueda; Rebecca Brooks; Lee-Lynn Chen; Lee-May Chen
Journal:  Obstet Gynecol       Date:  2016-07       Impact factor: 7.661

Review 2.  Enhanced recovery after gastro-intestinal surgery: The scientific background.

Authors:  P Mariani; K Slim
Journal:  J Visc Surg       Date:  2016-10-25       Impact factor: 2.043

3.  Enhanced Recovery After Surgery in Older Adults Undergoing Colorectal Surgery: A Systematic Review and Meta-analysis of Randomized Controlled Trials.

Authors:  Janani Thillainadesan; Minna F Yumol; Michael Suen; Sarah Hilmer; Vasi Naganathan
Journal:  Dis Colon Rectum       Date:  2021-08-01       Impact factor: 4.585

4.  Consensus guidelines for enhanced recovery after gastrectomy: Enhanced Recovery After Surgery (ERAS®) Society recommendations.

Authors:  K Mortensen; M Nilsson; K Slim; M Schäfer; C Mariette; M Braga; F Carli; N Demartines; S M Griffin; K Lassen
Journal:  Br J Surg       Date:  2014-07-21       Impact factor: 6.939

Review 5.  Uterine-sparing minimally invasive interventions in women with uterine fibroids: a systematic review and indirect treatment comparison meta-analysis.

Authors:  Nikoletta Panagiotopoulou; Shankaralingaiah Nethra; Stamatios Karavolos; Gaity Ahmad; Andreas Karabis; Amanda Burls
Journal:  Acta Obstet Gynecol Scand       Date:  2014-07-23       Impact factor: 3.636

6.  Postoperative Opioid Use Using Enhanced Recovery After Surgery Guidelines for Benign Gynecologic Procedures.

Authors:  Peter R Movilla; Jolene A Kokroko; Amalia G Kotlyar; Tami S Rowen
Journal:  J Minim Invasive Gynecol       Date:  2019-04-17       Impact factor: 4.137

7.  International validation of Enhanced Recovery After Surgery Society guidelines on enhanced recovery for gynecologic surgery.

Authors:  Lena Wijk; Ruzan Udumyan; Basile Pache; Alon D Altman; Laura L Williams; Kevin M Elias; Jake McGee; Tiffany Wells; Leah Gramlich; Kevin Holcomb; Chahin Achtari; Olle Ljungqvist; Sean C Dowdy; Gregg Nelson
Journal:  Am J Obstet Gynecol       Date:  2019-04-30       Impact factor: 8.661

8.  Impact of enhanced recovery after surgery (ERAS) protocol on gastrointestinal function in gynecologic oncology patients undergoing laparotomy.

Authors:  Teresa K L Boitano; Haller J Smith; Tullia Rushton; Mary C Johnston; Prentiss Lawson; Charles A Leath; Anisa Xhaja; Meredith P Guthrie; J Michael Straughn
Journal:  Gynecol Oncol       Date:  2018-09-21       Impact factor: 5.482

9.  In-bag manual versus uncontained power morcellation for laparoscopic myomectomy.

Authors:  Fulvio Zullo; Roberta Venturella; Antonio Raffone; Gabriele Saccone
Journal:  Cochrane Database Syst Rev       Date:  2020-05-06
View more
  2 in total

1.  Clarification of issues brought up by 'Is enhanced recovery after surgery protocol has high value in after laparoscopic myomectomy?'.

Authors:  Yulian Chen; Mingru Fu; Guifen Huang; Jiao Chen
Journal:  Gland Surg       Date:  2022-08

2.  Is enhanced recovery after surgery protocol has high value in after laparoscopic myomectomy?

Authors:  Qingbo Feng; Wenwei Liao; Xuping Feng; Jinpeng Du; Jiaxin Li
Journal:  Gland Surg       Date:  2022-08
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.